Cas:96736-11-7 Nourseothricin sulfate manufacturer & supplier

We serve Chemical Name:Nourseothricin sulfate CAS:96736-11-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Nourseothricin sulfate

Chemical Name:Nourseothricin sulfate
CAS.NO:96736-11-7
Synonyms:4-O-Carbamoyl-2-deoxy-2-{[(3S)-3,6-diaminohexanoyl]amino}-N-[(7R)-7-hydroxy-4-oxooctahydro-2H-imidazo[4,5-c]pyridin-2-ylidene]-α-L-glycero-hexopyranosylamine;MFCD00165013;α-L-glycero-Hexopyranosylamine, 2-deoxy-2-[[(3S)-3,6-diamino-1-oxohexyl]amino]-N-[(7R)-octahydro-7-hydroxy-4-oxo-2H-imidazo[4,5-c]pyridin-2-ylidene]-, 4-carbamate
Molecular Formula:C50H94N20O22S
Molecular Weight:502.522
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.9±0.1 g/cm3
Index of Refraction:1.790
PSA:276.87000
Exact Mass:502.249969
LogP:-5.12

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like 4-O-Carbamoyl-2-deoxy-2-{[(3S)-3,6-diaminohexanoyl]amino}-N-[(7R)-7-hydroxy-4-oxooctahydro-2H-imidazo[4,5-c]pyridin-2-ylidene]-α-L-glycero-hexopyranosylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,α-L-glycero-Hexopyranosylamine, 2-deoxy-2-[[(3S)-3,6-diamino-1-oxohexyl]amino]-N-[(7R)-octahydro-7-hydroxy-4-oxo-2H-imidazo[4,5-c]pyridin-2-ylidene]-, 4-carbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,α-L-glycero-Hexopyranosylamine, 2-deoxy-2-[[(3S)-3,6-diamino-1-oxohexyl]amino]-N-[(7R)-octahydro-7-hydroxy-4-oxo-2H-imidazo[4,5-c]pyridin-2-ylidene]-, 4-carbamate Use and application,4-O-Carbamoyl-2-deoxy-2-{[(3S)-3,6-diaminohexanoyl]amino}-N-[(7R)-7-hydroxy-4-oxooctahydro-2H-imidazo[4,5-c]pyridin-2-ylidene]-α-L-glycero-hexopyranosylamine technical grade,usp/ep/jp grade.


Related News: The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there. Valeriansaeure-vinylamid manufacturers “Partnering with a CDMO that has the skills and capabilities to execute a successful tech transfer is critical, as this complex, multi-step process helps lay the foundation for the new drug’s journey through to commercialization. (R)-N-allyloxyalanine benzyl ether suppliers In his new role, Grégoire will ensure alignment between NOVA’s business strategy, operations and growth objectives, as well as leading the Modelling and Simulation (M&S) team as NOVA embarks on its next phase of expansion. 3-hydroxy-2-[(3-methoxyphenyl)acetyl]cyclohex-2-en-1-one vendor & factory.